MedWatch

Demant plans to increase investments in China

Profits will take a back seat as the Danish hearing aid manufacturer makes growth a priority in the country, where newly acquired hearing aid clinic network Shengwang will drive the business.

Søren Nielsen, CEO of Demant | Photo: Kenneth Lysbjerg Koustrup/Jyllands-Posten/Ritzau Scanpix

No market in the world has growth potential matching China’s with respect to hearing aids and other hearing loss solutions, Demant CEO Søren Nielsen says, explaining why the Danish hearing aid manufacturer will be investing heavily in the East Asia region going forward.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs